Please try another search
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company was incorporated in 1991 and is based in Uppsala, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Lars Sunnanväder | - | 2005 | Non-Executive Director |
Henrik Krook | 48 | 2017 | Independent Non-Executive Director |
Adam Dahlberg | 48 | 2005 | Chairman |
Rutger Ploeg | - | 2017 | Scientific Advisor |
Gunilla Ekstrom | 63 | 2017 | Independent Non-Executive Director |
Magnus Nilsson | - | 2020 | Independent Non-Executive Director |
Thomas Lifvendahl | 54 | 2022 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review